<DOC>
	<DOCNO>NCT01928680</DOCNO>
	<brief_summary>It phase II trial explore efficacy safety cisplatin plus capecitabine anthracycline taxane-pretreated metastatic triple negative breast cancer patient .</brief_summary>
	<brief_title>Phase II Study Capecitabine Cisplatin Treat Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description>Cisplatin contain regimen demonstrate effective metastatic triple negative breast cancer patient phase II clinical trial . Meanwhile , Capecitabine also highly effective choice metastatic breast cancer considerable duration response . Combination cisplatin capecitabine prove effective metastatic breast cancer several phase II trial . This study aim investigate efficacy safety combination triple negative breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written sign inform consent prior begin specific protocol procedure . Pathologically confirm Estrogen Receptor ( ER ) , Progesterone Receptor ( PR ) Human Epidermal growth factor Receptor HER2 ) negative ( `` triple negative '' ) breast cancer document metastatic locally advanced disease . Measurable disease least 1 lesion measurable radiological method KPS &gt; =70 18 70 year old woman Previously treat anthracycline taxane Hormone therapy earlystage metastatic breast cancer permit hormonal receptor positive . Treatment Herceptin earlystage metastatic breast cancer permit HER2 positive Laboratory requirement : Hematology Absolute neutrophil count &gt; =1,500 /μl ; Platelets &gt; =100,000 /μl ; Hemoglobin &gt; =10 g/dl Liver function Total bilirubin &lt; =2 time ULN ASAT ( SGOT ) ALAT ( SGPT ) &lt; =2.5 time UNL without liver metastasis &lt; =5.0 time liver metastasis Glucose &lt; =200 mg/dL Renal function Serum creatinine &lt; =140 mol/l Life expectancy least 12 week Patients must accessible treatment followup . Patients recover acute reversible effect prior treatment . This generally mean least 3 week elapse since prior chemotherapy , adjuvant Neoadjuvant treatment . least 4 week since prior ( radical ) radiotherapy major surgery Women pregnant breast feed History brain and/or leptomeningeal metastasis Past current history malignant neoplasm breast carcinoma , except curatively treat non melanoma skin cancer , situ carcinoma cervix cancer curatively treat evidence disease least 5 year Preexisting neuropathy grade 1 accord NCICCTC 3.0 Psychiatric disorder condition would prevent pt . compliance Other serious illness medical condition : Congestive heart failure , unstable angina pectoris , previous history myocardial infarction within 6 month prior study entry , uncontrolled hypertension determine Investigator high risk uncontrolled , arrhythmia . History significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent . Active uncontrolled infection . Unstable peptic ulcer , unstable diabetes mellitus contraindication use Corticosteroids . Inability take and/or absorb oral medicine Prior treatment capecitabine and/or cisplatin Concurrent treatment experimental drug , participation another clinical trial investigational drug within 30 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Triple Negative Breast Cancer , Cisplatin , Capecitabine</keyword>
</DOC>